Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy

Everest Medicines announced that U.S. Food and Drug Administration has accepted the submission for the supplemental New Drug Application for Nefecon® from its partner Calliditas Therapeutics AB and granted Priority Review.